Table 1.
Baseline Characteristics of the Cohort (N = 20)
| Age, yrs | 61 ± 12 |
| Male | 13 (65.0) |
| Diabetes mellitus | 0 (0.0) |
| Hypertension | 7 (35.0) |
| TIA/CVA | 1 (5.0) |
| Ischemic heart disease | 1 (5.0) |
| Cardiac surgery | 1 (5.0) |
| Left ventricular EF ≥55% | 18 (90.0) |
| LA size, cm2 | |
| 20–30 | 17 (85.0) |
| 30–40 | 3 (15) |
| >40 | 0 (0.0) |
| AF duration, months | 13.5 ± 6.2 |
| Previous AT ablation | |
| Cavotricuspid isthmus-dependent flutter | 2 (10.0) |
| Current antiarrhythmic or rate-controlling strategy | |
| Beta-blockers including sotalol | 11 (55.0) |
| Amiodarone | 5 (25.0) |
| Flecainide | 1 (5.0) |
| Current anticoagulation strategy | |
| Warfarin | 6 (30.0) |
| Novel oral anticoagulants | 14 (70.0) |
Values are mean ± SD or n (%).
AF = atrial fibrillation; AT = atrial tachycardia; CVA = cerebrovascular accident; EF = ejection fraction; LA = left atrium; TIA = transient ischemic attack.